Bibliothèque

Chinese expert consensus on sequential surgery following conversion therapy based on combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2024 edition).

Up to half of hepatocellular carcinoma (HCC) cases are diagnosed at an advanced stage, for which effective treatment options are lacking, resulting in a poor prognosis. Over the past few years, the co…

Thérapies de Conversion

Tang, H., Zhang, W., Cao, J., Cao, Y., Bi, X., Zhao, H., Zhang, Z., Liu, Z., Wan, T., Lang, R., Sun, W., Du, S., Yang, Y., Lu, Y., Zeng, D., Wu, J., Duan, B., Lin, D., Li, F., … Editorial, B. o. a. r. d. . o. f. . t. h. e. . C. h. i. n. e. s. e. . J. o. u. r. n. a. l. . o. f. . H. e. p. a. t. o. b. i. l. i. a. r. y. . S. u. r. g. e. r. y. (2025). Chinese expert consensus on sequential surgery following conversion therapy based on combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2024 edition).. Biosci Trends, 18(6), 505-524. https://doi.org/10.5582/bst.2024.01394

14/01/2025 Lire →

Advances in systemic therapy leading to conversion surgery for advanced hepatocellular carcinoma.

Recently, a systemic therapy for advanced hepatocellular carcinoma (HCC) has been developed. The regimen for unresectable HCC varies and includes single or multi-tyrosine kinase inhibitors, monoclonal…

Thérapies de Conversion

Hakoda, H., Ichida, A., & Hasegawa, K. (2025). Advances in systemic therapy leading to conversion surgery for advanced hepatocellular carcinoma.. Biosci Trends, 18(6), 525-534. https://doi.org/10.5582/bst.2024.01372

14/01/2025 Lire →

Efficacy of Combined PD-1 Inhibitor and Bevacizumab in Unresectable Liver Metastasis of MSI-H Colorectal Cancer: A Case Report.

BACKGROUND Programmed death 1 (PD-1) inhibitors have demonstrated limited effectiveness in patients with microsatellite instability-high (MSI-H) colorectal cancer (CRC). Recent studies suggest that th…

Thérapies de Conversion

Wang, Q., Zhong, J., Wang, Y., Bao, J., Li, S., & Yang, L. (2025). Efficacy of Combined PD-1 Inhibitor and Bevacizumab in Unresectable Liver Metastasis of MSI-H Colorectal Cancer: A Case Report.. Am J Case Rep, 26, e946757. https://doi.org/10.12659/AJCR.946757

10/01/2025 Lire →

Treatment outcomes and prognostic factors in patients with colorectal cancer and synchronous lung metastases in the conversion therapy era.

PURPOSE: The Japanese Grade Classification based on the status of pulmonary and mesenteric nodal metastases and the presence of extrapulmonary metastases had a prognostic value in patients with colore…

Thérapies de Conversion

Nozawa, H., Suzuki, N., Tsushima, T., Murono, K., Sasaki, K., Emoto, S., Fujishiro, M., Sato, M., & Ishihara, S. (2025). Treatment outcomes and prognostic factors in patients with colorectal cancer and synchronous lung metastases in the conversion therapy era.. Int J Colorectal Dis, 40(1), 9. https://doi.org/10.1007/s00384-024-04799-1

09/01/2025 Lire →

Evaluation of Combined Lipiodol and Epirubicin-Loaded Drug-Eluting Bead Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma.

PURPOSE: To evaluate the short-term clinical efficacy, side effects and risk factors affecting the clinical effectiveness of the combination of lipidol and epirubicin-loaded drug-eluting bead transart…

Thérapies de Conversion

Song, D., Feng, X., Zhou, Y., Cai, Y., & Xue, T. (2025). Evaluation of Combined Lipiodol and Epirubicin-Loaded Drug-Eluting Bead Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma.. J Hepatocell Carcinoma, 12, 2723-2733. https://doi.org/10.2147/JHC.S565056

01/01/2025 Lire →

Tumor regression grade predicts recurrence-free survival in intermediate-advanced hepatocellular carcinoma after conversion therapy.

BACKGROUND: Conversion therapy provides patients with intermediate-advanced hepatocellular carcinoma (HCC) an opportunity for radical resection, but the prognostic significance of residual tumor in re…

Thérapies de Conversion

Zhang, H., Yang, T., Huang, L., Li, B., Xu, H., & Wei, Y. (2025). Tumor regression grade predicts recurrence-free survival in intermediate-advanced hepatocellular carcinoma after conversion therapy.. Front Immunol, 16, 1704239. https://doi.org/10.3389/fimmu.2025.1704239

01/01/2025 Lire →

Immunotherapy in conversion therapy for gastric cancer: current status, progress, and challenges.

Gastric cancer remains a global health burden due to its late diagnosis and poor prognosis. Conversion therapy aims to make the initially unresectable tumor resectable through systemic treatment, prov…

Thérapies de Conversion

Su, Y., Zhang, X., & Deng, W. (2025). Immunotherapy in conversion therapy for gastric cancer: current status, progress, and challenges.. Front Oncol, 15, 1637657. https://doi.org/10.3389/fonc.2025.1637657

01/01/2025 Lire →

Screening Candidates for Conversion Therapy in Unresectable Hepatocellular Carcinoma Patients After Tyrosine Kinase Inhibitor Plus PD-1/PD-L1 Antibody Therapy: A Multicenter Retrospective Study.

BACKGROUND: Conversion therapies after immune checkpoint inhibitors (ICIs) plus tyrosine-kinase inhibitors (TKIs) provide curative surgery chance and prolong survival for unresectable hepatocellular c…

Thérapies de Conversion

Jin, Z., Li, X., Lv, L., Zhang, B., Ma, X., Chen, S., You, J., Wu, X., Wang, L., Liu, X., Wang, F., Chen, X., Yu, L., Zhang, S., & Zhang, L. (2025). Screening Candidates for Conversion Therapy in Unresectable Hepatocellular Carcinoma Patients After Tyrosine Kinase Inhibitor Plus PD-1/PD-L1 Antibody Therapy: A Multicenter Retrospective Study.. J Hepatocell Carcinoma, 12, 1921-1941. https://doi.org/10.2147/JHC.S523476

01/01/2025 Lire →

Rare Gingival Metastasis Occurring After Conversion Therapy Followed by Resection of Initially Unresectable Hepatocellular Carcinoma: A Case Report.

Gingival metastases from hepatocellular carcinoma (HCC) are exceedingly rare and highly prone to be misdiagnosed without biopsy. Here, we report an initially unresectable HCC patient who received effe…

Thérapies de Conversion

Zhan, J., Huang, H., Zhan, T., Liu, X., & Cheng, Q. (2025). Rare Gingival Metastasis Occurring After Conversion Therapy Followed by Resection of Initially Unresectable Hepatocellular Carcinoma: A Case Report.. J Hepatocell Carcinoma, 12, 705-713. https://doi.org/10.2147/JHC.S514983

01/01/2025 Lire →

Development of a Nomogram for Prognostic Prediction of Large Hepatocellular Carcinoma With HBV After TACE Combined Conversion Therapy.

BACKGROUND: Surgical resection (SR) following transarterial chemoembolization (TACE) is a promising option for large hepatocellular carcinoma (LHCC) with HBV, and identification of these patients at h…

Thérapies de Conversion

Xu, W., Ding, X., Xu, Y., Zhang, Y., Xu, H., Guo, L., & Li, L. (2025). Development of a Nomogram for Prognostic Prediction of Large Hepatocellular Carcinoma With HBV After TACE Combined Conversion Therapy.. Hepat Med, 17, 1-12. https://doi.org/10.2147/HMER.S481334

01/01/2025 Lire →

Systemic Treatment for Unresectable Hepatocellular Carcinoma: A Surgeon's Perspective.

In recent years, the standard treatment for hepatocellular carcinoma (HCC) has changed dramatically due to the emergence of potent systemic treatment options. These advanced therapies have led to incr…

Thérapies de Conversion

Zhu, X. D., Zhao, L., Li, B., Cheng, Y., & Sun, H. C. (2025). Systemic Treatment for Unresectable Hepatocellular Carcinoma: A Surgeon's Perspective.. J Hepatocell Carcinoma, 12, 399-413. https://doi.org/10.2147/JHC.S504457

01/01/2025 Lire →

ASO Author Reflections: Can Conversion Therapy be an Option for Advanced Esophageal Cancer with Distant Metastases?

Thérapies de Conversion

Tsuji, T., Matsuda, S., Sato, Y., Tanaka, K., Sasaki, K., Watanabe, M., Hamai, Y., Nasu, M., Saze, Z., Nakashima, Y., Nomura, M., Yamamoto, S., Booka, E., Ishiyama, K., Bamba, T., Sakanaka, K., Tsushima, T., Takeuchi, H., Kato, K., & Kawakubo, H. (2025). ASO Author Reflections: Can Conversion Therapy be an Option for Advanced Esophageal Cancer with Distant Metastases?. Ann Surg Oncol, 32(1), 325-326. https://doi.org/10.1245/s10434-024-16310-9

01/01/2025 Lire →